Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of GnRH and Raloxifen on the size of uterine lyomioma

Trial Profile

Effects of GnRH and Raloxifen on the size of uterine lyomioma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raloxifene (Primary) ; Gonadotropin releasing hormone
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2014 New trial record
    • 05 May 2013 Iranian Registry of Clinical Trials reports recruitment completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top